A novel mutation in CD40 and its functional characterization

Human Mutation

Volumn 30, Issue 6, 2009, Pages 985-994

  Qi, Chun Jian ^a,b   Zheng, Lu ^a   Ma, Hong Bing ^a   Fei, Min ^a   Qian, Ke Qing ^b   Shen, Bai Rong ^a,c   Wu, Chang Ping ^a   Vihinen, Mauno ^c,d   Zhang, Xue Guang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TAMPERE   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

AS PCR; CD40; Genotype phenotype; Signalosome

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; EPITOPE;

ARTICLE; BINDING AFFINITY; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ANNEXIN A5; ANTIGENS, CD40; APOPTOSIS; B-LYMPHOCYTES; CD40 LIGAND; CELL LINE, TUMOR; CELL SEPARATION; GENOTYPE; HUMANS; IMMUNOPRECIPITATION; MICE; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PHENOTYPE; PROTEIN BINDING; PROTEIN TRANSPORT; THERMODYNAMICS; TRANSFECTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 66349083821     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20967     Document Type: Article

References (50)

1. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. 1999. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J Exp Med 189:441-446. (Pubitemid 29063265)
2. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. 1993. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669-674. (Pubitemid 23218216)
3. Bajorath J, Marken JS, Chalupny NJ, Spoon TL, Siadak AW, Gordon M, Noelle RJ, Hollenbaugh D, Aruffo A. 1995. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry 34:9884-9892.
4. Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A. 1998. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 103:270-275. (Pubitemid 28470831)
5. Combet C, Jambon M, Deleage G, Geourjon C. 2002. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics 18:213-214. (Pubitemid 34145058)
6. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. 2004a. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res 32(Web Server issue):W96-W99. (Pubitemid 38997307)
7. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. 2004b. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20:45-50. (Pubitemid 38088339)
8. Dallman C, Johnson PW, Packham G. 2003. Differential regulation of cell survival by CD40. Apoptosis 8:45-53. (Pubitemid 36133137)
9. Durie BG, Salmon SE. 1975. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854.
10. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, Young LS. 1996. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13:2243-2254. (Pubitemid 26411575)
11. French AP, Mills S, Swarup R, Bennett MJ, Pridmore TP. 2008. Colocalization of fluorescent markers in confocal microscope images of plant cells. Nat Protoc 3:619-628.
12. Geourjon C, Combet C, Blanchet C, Deleage G. 2001. Identification of related proteins with weak sequence identity using secondary structure information. Protein Sci 10:788-797. (Pubitemid 32240505)
13. Goddard TD, Huang CC, Ferrin TE. 2005. Software extensions to UCSF Chimera for interactive visualization of large molecular assemblies. Structure 13:473-482. (Pubitemid 40342886)
14. Goddard TD, Huang CC, Ferrin TE. 2007. Visualizing density maps with UCSF Chimera. J Struct Biol 157:281-287. (Pubitemid 44880787)
15. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A. 1992. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 11:4313-4321.
16. Jabara HH, Buckley RH, Roberts JL, Lefranc G, Loiselet J, Khalil G, Geha RS. 1998. Role of JAK3 in CD40-mediated signaling. Blood 92:2435-2440. (Pubitemid 28452986)
17. Jaffe ES, Sander CA, Flaig MJ. 2000. Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification. Ann Oncol 11(Suppl 1):17-21. (Pubitemid 30111860)
18. Jalukar SV, Hostager BS, Bishop GA. 2000. Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J Immunol 164:623-630. (Pubitemid 30043681)
19. Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K, Garber E, Hsu YM. 2001. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9:321-329. (Pubitemid 32772577)
20. Lafage-Pochitaloff M, Herman P, Birg F, Galizzi JP, Simonetti J, Mannoni P, Banchereau J. 1994. Localization of the human CD40 gene to chromosome 20, bands q12-q13.2. Leukemia 8:1172-1175. (Pubitemid 24224521)
21. Lee HH, Dempsey PW, Parks TP, Zhu X, Baltimore D, Cheng G. 1999. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci USA 96:1421-1426. (Pubitemid 29098466)
22. Lollini PL, Landuzzi L, Frabetti F, Rossi I, Nicoletti G, Scotlandi K, Serra M, Baldini N, De Giovanni C, Nanni P. 1998. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 4:1843-1849. (Pubitemid 28369166)
23. Lougaris V, Badolato R, Ferrari S, Plebani A. 2005. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 203:48-66. (Pubitemid 40179693)
24. Meng EC, Pettersen EF, Couch GS, Huang CC, Ferrin TE. 2006. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics 7:339. (Pubitemid 44404352)
25. Merchionne F, Perosa F, Dammacco F. 2007. New therapies in multiple myeloma. Clin Exp Med 7:83-97. (Pubitemid 350045116)
26. O'Sullivan B, Thomas R. 2003. CD40 and dendritic cell function. Crit Rev Immunol 23:83-107. (Pubitemid 36875475)
27. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P. 1985. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 20:23-28. (Pubitemid 15238919)
28. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, Ford RJ. 2002. A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 16:37-50. (Pubitemid 34143215)
29. Qi CJ, Zheng L, Zhou X, Tao Y, Ge Y, Zhuang YM, Xu Y, Yu G, Zhang XG. 2004. Cross-linking of CD40 using anti-CD40 antibody, 5C11, has different effects on XG2 multiple myeloma cells. Immunol Lett 93:151-158. (Pubitemid 38670368)
30. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, Ferradini L, Bosq J, Tursz T, Busson P. 1999. Control of apoptosis in Epstein-Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 59:924-930. (Pubitemid 29086750)
31. Schjetne KW, Fredriksen AB, Bogen B. 2007. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 178:4169-4176. (Pubitemid 46492367)
32. Schonbeck U, Libby P. 2001. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58:4-43. (Pubitemid 32143961)
33. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. 2005. The FoldX web server: an online force field. Nucleic Acids Res 33(Web Server issue): W382-W388. (Pubitemid 44529948)
34. Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, Naismith JH, Thomas D. 1998. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci 7:1124-1135. (Pubitemid 28237044)
35. Tai YT, Podar K, Gupta D, Lin B, Young G, Akiyama M, Anderson KC. 2002. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 99:1419-1427. (Pubitemid 34547100)
36. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC. 2004. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64:2846-2852. (Pubitemid 38500624)
37. Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H. 2001. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci USA 98:1751-1756. (Pubitemid 32165570)
38. Tong AW, Zhang BQ, Mues G, Solano M, Hanson T, Stone MJ. 1994. Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 84:3026-3033. (Pubitemid 24328094)
39. Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, Netto G, Stone MJ. 2000. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma 36:543-558. (Pubitemid 30103180)
40. Tong AW, Stone MJ. 2003. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10:1-13. (Pubitemid 36222071)
41. Tovchigrechko A, Vakser IA. 2005. Development and testing of an automated approach to protein docking. Proteins 60:296-301. (Pubitemid 40934902)
42. Tovchigrechko A, Vakser IA. 2006. GRAMM-X public web server for protein-protein docking. Nucleic Acids Res 34(Web Server issue):W310-W314. (Pubitemid 44529784)
43. Voorzanger-Rousselot N, Favrot M, Blay JY. 1998. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 92:3381-3387. (Pubitemid 28492348)
44. Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ. 2001. Molecular characterization of CD40 signaling intermediates. J Biol Chem 276:43334-43342. (Pubitemid 37371023)
45. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF. 1994. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL- secretion by a human myeloma cell line. J Immunol 152:117-128. (Pubitemid 24009748)
46. Wu DY, Ugozzoli L, Pal BK, Wallace RB. 1989. Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci USA 86:2757-2760. (Pubitemid 19112620)
47. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. 1998. CD40 and epithelial cells: across the great divide. Immunol Today 19:502-506. (Pubitemid 28518027)
48. Zapata JM, Reed JC. 2002. TRAF1: lord without a RING. Sci STKE 2002:PE27.
49. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B. 1994. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654-3663. (Pubitemid 24175556)
50. Zhou ZH, Wang JF, Wang YD, Qiu YH, Pan JZ, Xie W, Jiang LY, Klein B, Zhang XG. 1999. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. Hybridoma 18:471-478. (Pubitemid 30020608)